Gland Pharma Limited — Important, 31-07-2025: Updates

Gland Pharma's Business Responsibility & Sustainability Report for FY25 demonstrates strong ESG commitment. The company achieved reduced energy intensity and GHG emissions per unit of turnover, supported by solar power adoption and advanced wastewater treatment. Operations globally include 7 national and 4 international plants, with exports contributing ~89% of turnover. FY25 turnover stood at ₹4,116 Cr and net worth at ₹9,755 Cr. Gland Pharma reported zero external regulatory fines and ensured 100% of employees were paid above minimum wage. Employee grievances related to sexual harassment saw 3 complaints in FY25 (up from 1), all addressed. No product recalls or data breaches.